218 related articles for article (PubMed ID: 18832842)
1. Economic reflections on proton pump inhibitor therapy for non-erosive reflux disease.
Moayyedi P
Digestion; 2008; 78 Suppl 1():61-9. PubMed ID: 18832842
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
Harris RA; Kuppermann M; Richter JE
Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
[TBL] [Abstract][Full Text] [Related]
3. Re-examination of the cost-effectiveness of surgical versus medical therapy in patients with gastroesophageal reflux disease: the value of long-term data collection.
Arguedas MR; Heudebert GR; Klapow JC; Centor RM; Eloubeidi MA; Wilcox CM; Spechler SJ;
Am J Gastroenterol; 2004 Jun; 99(6):1023-8. PubMed ID: 15180720
[TBL] [Abstract][Full Text] [Related]
4. Management strategies for gastroesophageal reflux disease.
Bak YT
J Gastroenterol Hepatol; 2004 Sep; 19 Suppl 3():S49-53. PubMed ID: 15324382
[TBL] [Abstract][Full Text] [Related]
5. Maintenance treatment with proton pump inhibitors for reflux esophagitis in pediatric patients: a systematic literature analysis.
Illueca M; Wernersson B; Henderson C; Lundborg P
J Pediatr Gastroenterol Nutr; 2010 Dec; 51(6):733-40. PubMed ID: 20808247
[TBL] [Abstract][Full Text] [Related]
6. Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.
Komatsu-Tanaka M; Iwakiri R; Fujimoto K; Fujiwara Y; Inamori M; Tanaka J; Shimatani T; Akiyama J; Ando T; Manabe N; Kinjo F; Deguchi R; Kusano M
Dig Endosc; 2012 Nov; 24(6):407-11. PubMed ID: 23078431
[TBL] [Abstract][Full Text] [Related]
7. Disease-specific cost savings of treating nighttime versus daytime gastroesophageal reflux disease in an employed population.
Doan QV; Lange SM; Elfant A; Aguilar D; Reyes E; Lynn RB; Dubois RW
J Med Econ; 2008; 11(1):23-40. PubMed ID: 19450108
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness model of endoscopic biopsy for eosinophilic esophagitis in patients with refractory GERD.
Miller SM; Goldstein JL; Gerson LB
Am J Gastroenterol; 2011 Aug; 106(8):1439-45. PubMed ID: 21448144
[TBL] [Abstract][Full Text] [Related]
9. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
Abel C; Desilets AR; Willett K
Ann Pharmacother; 2010 May; 44(5):871-7. PubMed ID: 20371754
[TBL] [Abstract][Full Text] [Related]
10. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis.
Weijenborg PW; Cremonini F; Smout AJ; Bredenoord AJ
Neurogastroenterol Motil; 2012 Aug; 24(8):747-57, e350. PubMed ID: 22309489
[TBL] [Abstract][Full Text] [Related]
11. Potential options to optimize therapy of gastroesophageal reflux disease with proton pump inhibitors.
Tonini M; Vigneri S; Neri M; Cuomo R; Savarino V; Pace F
Digestion; 2007; 76(3-4):171-8. PubMed ID: 18046084
[TBL] [Abstract][Full Text] [Related]
12. Economic considerations in the treatment of gastroesophageal reflux disease: a review.
O'Connor JB; Provenzale D; Brazer S
Am J Gastroenterol; 2000 Dec; 95(12):3356-64. PubMed ID: 11151862
[TBL] [Abstract][Full Text] [Related]
13. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
Emerson CR; Marzella N
Clin Ther; 2010 Aug; 32(9):1578-96. PubMed ID: 20974316
[TBL] [Abstract][Full Text] [Related]
14. Is the use of esomeprazole in gastroesophageal reflux disease a cost-effective option in Poland?
Petryszyn P; Staniak A; Grzegrzolka J
J Comp Eff Res; 2016 Mar; 5(2):169-78. PubMed ID: 26946951
[TBL] [Abstract][Full Text] [Related]
15. The impact of pre-endoscopy proton pump inhibitor use on the classification of non-erosive reflux disease and erosive oesophagitis.
Gaddam S; Wani S; Ahmed H; Maddur P; Hall SB; Gupta N; Puli SR; Higbee A; Rastogi A; Bansal A; Sharma P
Aliment Pharmacol Ther; 2010 Nov; 32(10):1266-74. PubMed ID: 20955446
[TBL] [Abstract][Full Text] [Related]
16. The evolution of proton pump inhibitors for the treatment of gastroesophageal reflux disease.
Friedlander EA; Pallentino J; Miller SK; VanBeuge SS
J Am Acad Nurse Pract; 2010 Dec; 22(12):674-83. PubMed ID: 21129076
[TBL] [Abstract][Full Text] [Related]
17. Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors.
Kothari S; Nelson SP; Wu EQ; Beaulieu N; McHale JM; Dabbous OH
Curr Med Res Opin; 2009 Nov; 25(11):2703-9. PubMed ID: 19775195
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitor utilization patterns in infants.
Barron JJ; Tan H; Spalding J; Bakst AW; Singer J
J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):421-7. PubMed ID: 18030207
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage.
Spiegel BM; Dulai GS; Lim BS; Mann N; Kanwal F; Gralnek IM
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):988-997. PubMed ID: 16844422
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.
Saini SD; Schoenfeld P; Fendrick AM; Scheiman J
Arch Intern Med; 2008 Aug; 168(15):1684-90; discussion 1691. PubMed ID: 18695083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
